StockData
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31

Merck & Co., Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)

Close on Oct 19, 2026

Market cap
$354.77B
P/E (TTM)
114.9
Dividend yield
2.28%

Earnings

Next report expected Oct 29, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026Before market open$16.60B$-0.54$-0.13
Q1 FY2026
Ended Mar 31, 2026
Apr 30, 2026Before market open$16.30B$-1.72$-1.28
Q4 FY2025
Ended Dec 31, 2025
Feb 3, 2026Before market open$16.40B$1.19$2.04
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025Before market open$17.30B$2.32$2.58
Q2 FY2025
Ended Jun 30, 2025
Jul 29, 2025Before market open–––
Q1 FY2025
Ended Mar 31, 2025
Apr 24, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Feb 4, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Oct 31, 2024Before market open–––
Q2 FY2024
Ended Jun 30, 2024
Jul 30, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
Apr 25, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 1, 2024Before market open–––

Company guidance

Outlook given with results on Aug 4, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Non-GAAP EPSnon-GAAPFull Year 2026$2.66 to $2.76Lowered
Non-GAAP Gross marginnon-GAAPFull Year 202681%Lowered
Non-GAAP Effective income tax ratenon-GAAPFull Year 202635% to 36%Raised
Non-GAAP Operating expensesnon-GAAPFull Year 2026$42.00B to $42.70BRaised
Non-GAAP Other (income) expense, netnon-GAAPFull Year 2026$1.40BLowered
SalesFull Year 2026$66.30B to $67.30BRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Merck filed with the SEC